Registration
|
08:15 - 09:00 |
Welcome note by MarketsandMarkets
|
09:00 - 09:05 |
Opening remarks by the Chairperson
Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB
|
09:05 - 09:10 |
Data Quality and Standardization |
Use of patient reported outcomes in real-world evidence: Prurigo Nodularis as an example.
Donia Bahloul, Global and US HEOR Business Partner, Global Health Economics & Value Assessment, Sanofi
|
09:10 - 09:40 |
RWE in the EU Joint Clinical Assessment- Opportunities and Challenges?
Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB
|
09:40 - 10:10 |
Electronic Health Record meets Evidence
Ralf Patsch, Head of Real-World Data Business Germany, Cegedim
|
10:10 - 10:40 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meeting
|
10:40 - 11:30 |
RWE for Health Technology Assessment (HTA) |
The Power of High-Quality Real-World Data in Oncology
Maike Sauer, Head of Network & Commercial Partnerships, Flatiron Health
|
11:30 - 12:00 |
The Statistical Abyss that is RWE for HTA
Martin Scott, Scientific Director, Numerus
|
12:00 - 12:30 |
Methodological considerations with the development and implementation of external control arms using routine electronic health records
Lewis Carpenter, Director Real World Evidence, Arcturis Data
|
12:30 - 13:00 |
Lunch and Poster Presentation | One-to-One Networking
|
13:00 - 14:00 |
Post-Marketing Surveillance and Phase IV Trials |
Population adjusted RCTs – an option for long-term comparisons?
Michael Happich, Sr Director HTA, International Markets, Eli Lilly and Company
|
14:00 - 14:30 |
Real-life demonstrations of AI in practice for Market Access & HEOR teams
Thomas Gilboy, Owner- Market Access Digital Tools, Access Infinity
|
14:30 - 15:00 |
Panel Discussion- RWE in assessing long-term safety and effectiveness of interventions.
Lewis Carpenter, Director Real World Evidence, Arcturis Data
Alexandre Templier, Co-founder and President, Quinten Health
Ralf Patsch, Head of Real-World Data Business Germany, Cegedim
Martin Scott, Scientific Director, Numerus
Donia Bahloul, Global and US HEOR Business Partner, Global Health Economics & Value Assessment, Sanofi
|
15:00 - 15:40 |
Evening Refreshments and Poster Presentation | One-to-One Networking
|
15:40 - 16:25 |
Patient Recruitment and Retention |
Bridging the chasm between successful clinical trials and long-term Benefit/Risk and medico-economic impact demonstration: towards mutualized disease-centric cohort simulators
Alexandre Templier, Co-founder and President, Quinten Health
|
16:25 - 16:55 |
Real world influence of real world evidence for policy decision making at NICE’
Vandana Ayyar-Gupta, Scientific Adviser, Data & Analytics, National Institute for Health, and Care Excellence
|
16:55 - 17:25 |
Closing Remarks from the Chairperson
Sandeep Kiri, UCB Global Payer Value Strategy- Head of Health Economics and HTA Evidence, UCB
|
17:25 - 17:25 |